Superpowers for Good should not be considered investment advice. Seek counsel before making investment decisions. When you purchase an item, launch a campaign or create an investment account after clicking a link here, we may earn a fee. Engage to support our work.
Watch the show on television by downloading the e360tv channel app to your Roku, LG or AmazonFireTV. You can also see it on YouTube.
Devin: What is your superpower?
Dr. Dale: When I run into a problem, the first thing I have to do is tell myself, don’t be afraid. You’ve solved other problems in the past. You can solve this one.
Millions of people worldwide face the devastating impact of cancer, with countless lives lost each year to tumors that no longer respond to existing treatments. Dr. Dale Walker, Co-founder and CEO of The Burlington HC Research Group (BHCRG), is working to change that narrative with her groundbreaking development of a new family of anti-cancer drugs. These drugs have the potential to revolutionize treatment for cancers that have become resistant to current therapies.
“We tested our drugs against 15 human cancer cell lines, representative of seven different tissues, and the drug works against all of them,” Dale explained. In the U.S. alone, over 600,000 people die annually from cancer, often because their tumors no longer respond to treatment. Dale’s research offers a glimmer of hope for patients and their families.
Unlike traditional drug development that focuses on a single compound, Dale and her team have created a family of drugs—called BRG drugs—by combining two FDA-approved ingredients in a novel way. These drugs not only enhance the effectiveness of existing cancer treatments but also demonstrate the ability to kill nearly all cancer cells after a single dose in preclinical studies. “Most anti-cancer agents just slow tumor growth. Ours hit both marks—killing tumor cells at a safe dose level,” she said.
With such promising results, Dale and her husband Vernon, who co-leads the research, are pushing forward. However, taking these drugs through the necessary safety and efficacy tests requires significant funding. To accelerate progress, BHCRG is raising capital through a regulated crowdfunding campaign on the FundingHope platform. Crowdfunding offers a faster alternative to traditional funding sources, enabling the Walkers to bypass lengthy government grant timelines.
“Crowdfunding is a lifeline. We have family members and friends with cancer. We can’t wait years,” Dale shared. For investors, the opportunity to back a potential game-changing cancer therapy is compelling, both for its societal impact and long-term financial potential.
Dale’s passion and perseverance shine through in her work. Her innovative approach to drug development could save countless lives. Supporting her mission on Funding Hope isn’t just an investment in a company—it’s an investment in hope.
tl;dr:
Dale Walker shares her innovative work on new anti-cancer drugs targeting resistant tumors.
BHCRG’s BRG drugs show promising preclinical results, killing almost all tumor cells with one dose.
Dale explains crowdfunding’s role in accelerating drug development for life-saving cancer treatments.
She discusses perseverance as her superpower, solving challenges by embracing and examining problems.
Today’s episode highlights how crowdfunding enables investors to support impactful innovations in healthcare.
How to Develop Perseverance in Problem-Solving As a Superpower
Dale’s superpower is her extraordinary ability to solve complex problems and persevere through challenges. In today’s episode, she explained, “When I run into a problem, the first thing I have to do is tell myself, don’t be afraid. You’ve solved other problems in the past. You can solve this one.” Dale emphasized that problems often contain valuable information that leads to solutions, encouraging others to examine challenges closely rather than avoiding them.
After discovering that an FDA-approved drug had antiviral activity, Dale faced a seemingly insurmountable challenge: making the drug work effectively in people. “I thought, I will not be able to solve this problem. It’s too hard,” she admitted. Yet, she persevered, combining the drug with another FDA-approved ingredient. This breakthrough created the BRG family of cancer drugs, which kill nearly all cancer cells in preclinical studies after a single dose. Her ability to persist through doubt and difficulty exemplifies her superpower.
Tips for Developing Perseverance in Problem-Solving:
Acknowledge Your Strengths: Remind yourself that you’ve solved tough problems before and can do it again.
Examine Problems Closely: Instead of avoiding challenges, look for clues within the problem itself to guide solutions.
Break Down the Problem: Address each component of the challenge one step at a time.
Stay Focused: Resist the urge to pivot too quickly; often, solutions lie in persistence.
Find Inspiration: Remember the impact your work can have on others to stay motivated.
By following Dale’s example and advice, you can make perseverance in problem-solving a skill. With practice and effort, you could make it a superpower that enables you to do more good in the world.
Remember, however, that research into success suggests that building on your own superpowers is more important than creating new ones or overcoming weaknesses. You do you!
Guest Profile
Dale M. Walker (she/her):
Co-founder, owner, and Chief Executive Officer, The Burlington HC Research Group, Inc. (BHCRG)
About The Burlington HC Research Group, Inc. (BHCRG): BHCRG is working to advance a new family of investigational drugs called BRG Therapeutics. Based on pre-clinical studies, two members of this family show potent anticancer activity across human cancer cell lines representing seven different tissues of origin, including lung cancer (four subtypes), prostate cancer (three types), triple-negative breast cancer (two types), ovarian cancer (two types), pancreatic cancer (one type), pleural mesothelioma (two types), and pre-myeloblastic leukemia (one type, tested with a single BRG drug). In tissue-culture models, BRG drugs demonstrate an unusually strong ability to eliminate nearly all cancer cells after a single dose while achieving this result at doses that are non-toxic to normal human cells. Each BRG drug delivers two active ingredients, and the primary component (ingredient #1) also inhibits the replication of viruses spanning all three major viral genome classes—DNA viruses, RNA viruses, and reverse-transcribing/retroviruses—with activity shown in vitro against influenza, COVID-19, HIV, and Ebola and other viruses. Although such breadth is uncommon and has led some observers to believe no drug could achieve these effects, the evidence shows that the human body naturally produces several essential compounds with similarly broad anticancer and antiviral functions; BRG drugs work through analogous biochemical mechanisms but produce stronger effects in controlled laboratory studies. These naturally occurring comparators include N-acetylcysteine, glutathione, and vitamin C (only at pharmacologic doses). Taken together, BRG Therapeutics represents a next-generation, multi-targeted approach designed to overcome one of the central limitations of modern oncology—drug resistance—by restoring normal cellular regulation, reactivating p53, correcting redox imbalance, and neutralizing reactive species to selectively eliminate cancer cells while preserving healthy tissue.
Website: bhcrg.com
Company Facebook Page: facebook.com/profile.php?id=61584197824692
Other URL: invest.fundinghope.com/offering/brg/details
Biographical Information: My husband Vernon and I work together as a team, and we have advanced BRG therapeutics to their present state of development by collaboration. We both are veterinarians with advanced training in pathology, so that make us ‘veterinary pathologists’. Vernon also has a PhD in experimental and molecular pathology. What many people do not know is that veterinary pathologists have key roles in drug development and safety testing. Before the discovery of the BRG drugs, most of our work focused on health risks from human exposures to environmental, workplace, or medicinal agents/compounds. We were working with BRG active ingredient #1, which is FDA-approved as the active form of a cell protective drug – that means that it protects normal cells from the damaging effects of radiation and some chemicals. We were testing the ability of this agent to protect normal cells from the deleterious effects of some of the first drugs like AZT developed to treat HIV. We were surprised to learn that this cell protective drug had antiviral activity all on its own. Even though this active ingredient had been around for several decades, no one had ever reported these results before we did.
We soon learned why we were the first to make this discovery - the active ingredient of this cell protective drug worked well in tissue culture as an antiviral agent, but antiviral effects were not achieved in living animals. This sent us on a long road figuring out why this was – after all, this agent worked to protect normal cells in living animals and people, so why would it not work as an antiviral agent in the same animals and people? It actually took several years to understand the nature of the problems, and even more time to figure out a solution. That solution was the BRG therapeutics.
Vernon and I had little experience studying viruses, and much more experience studying cancer and anticancer drugs, and we knew that this active ingredient had anticancer activity, so we decided to start with testing a BRG drug as an anticancer agent. Our first experiment in a human, pre-myeloblastic leukemia cell line showed us anticancer effects beyond anything that we could have imagined. We were so excited, but we still had a long journey of work and discovery ahead of us. To date we have tested two BRG drugs and they kill cancer cells in all human cancer cell lines tested to date (one drug tested in 15 human cancers, the other tested in 14). A paper summarizing these results was published in 2023.
LinkedIn Profile: linkedin.com/in/dale-m-walker-bhcrg
Personal Facebook Profile: facebook.com/profile.php?id=61556212335476
Support Our Sponsors
Our generous sponsors make our work possible, serving impact investors, social entrepreneurs, community builders and diverse founders. Today’s advertisers include FundingHope, and SuperGreen Live. Learn more about advertising with us here.
Max-Impact Members
(We’re grateful for every one of these community champions who make this work possible.)
Brian Christie, Brainsy | Cameron Neil, Lend For Good | Carol Fineagan, Independent Consultant | Hiten Sonpal, RISE Robotics | John Berlet, CORE Tax Deeds, LLC. | Justin Starbird, The Aebli Group | Lory Moore, Lory Moore Law | Mark Grimes, Networked Enterprise Development | Matthew Mead, Hempitecture | Michael Pratt, Qnetic | Mike Green, Envirosult | Dr. Nicole Paulk, Siren Biotechnology | Paul Lovejoy, Stakeholder Enterprise | Pearl Wright, Global Changemaker | Scott Thorpe, Philanthropist | Sharon Samjitsingh, Health Care Originals | Add Your Name Here
Upcoming SuperCrowd Event Calendar
If a location is not noted, the events below are virtual.
Superpowers for Good Live Pitch, December 11, 2025, at 8:00 PM Eastern / 5:00 PM Pacific, will bring together four mission-driven founders—Fran Maier (BabyQuip), Farooq Zama (CureValue), Andrei Evulet (Jetoptera), and Erin Martin (Pump For Joy)—as they present their companies live to a national audience on e360tv, YouTube, and LinkedIn. Hosted by Devin Thorpe, CEO and Founder of The Super Crowd, Inc., this special broadcast showcases entrepreneurs raising capital to solve real-world problems across family travel, healthcare access, disaster response aviation, and maternal health. Viewers are encouraged to watch the live pitches and then continue the experience by joining the Private Investor Session immediately following the broadcast, where attendees can engage directly with founders, ask deeper questions, and explore their active investment offerings in a focused, off-air environment. Whether you are an active investor or simply interested in the future of mission-driven innovation, this event offers a rare opportunity to witness purpose-driven companies in action and connect with them directly after the show.
Impact Cherub Club Meeting hosted by The Super Crowd, Inc., a public benefit corporation, on December 16, 2025, at 1:30 PM Eastern. Each month, the Club meets to review new offerings for investment consideration and to conduct due diligence on previously screened deals. To join the Impact Cherub Club, become an Impact Member of the SuperCrowd.
SuperCrowdHour, December 17, 2025, at 12:00 PM Eastern, will feature Devin Thorpe, CEO and Founder of The Super Crowd, Inc., leading a session on “Designing a Winning Marketing Strategy for Your Investment Offering.” Drawing on his deep experience in impact crowdfunding and investment storytelling, Devin will break down the essential elements of building a marketing strategy that attracts, engages, and converts potential investors. Participants will learn how to identify and reach the right audience, craft messages that build trust, and develop a promotional plan that supports sustained momentum throughout a raise. Whether you’re preparing for your first regulated investment crowdfunding campaign or looking to strengthen an ongoing one, this SuperCrowdHour will provide the insights and practical frameworks you need to elevate your offering and boost investor participation.
SuperGreen Live, January 22–24, 2026, livestreaming globally. Organized by Green2Gold and The Super Crowd, Inc., this three-day event will spotlight the intersection of impact crowdfunding, sustainable innovation, and climate solutions. Featuring expert-led panels, interactive workshops, and live pitch sessions, SuperGreen Live brings together entrepreneurs, investors, policymakers, and activists to explore how capital and climate action can work hand in hand. With global livestreaming, VIP networking opportunities, and exclusive content, this event will empower participants to turn bold ideas into real impact. Don’t miss your chance to join tens of thousands of changemakers at the largest virtual sustainability event of the year.
Community Event Calendar
If you would like to submit an event for us to share with the 10,000+ changemakers, investors and entrepreneurs who are members of the SuperCrowd, click here.
We use AI to help us write compelling recaps of each episode.
